Posts by: Isaura Santos

Isaura Santos

Isaura Santos graduated with a BS in Cell and Molecular Biology from Universidade Nova de Lisboa and a MA in Communication, Culture and Information Technologies from University Institute of Lisbon (ISCTE-IUL). Her professional interests include science communication, public awareness of science and communication of science through entertainment.

April 13, 2015April 13, 2015

Northwest Biotherapeutics Reports Promising Survival Data In Glioblastoma Multiforme Patients Treated With DCVAX®-L

News

Northwest Biotherapeutics, Inc., a biotechnology company advancing DCVax personalized immune therapies to treat cancer, has recently announced that the Firm’s Chief Technical Officer Dr. Marnix Bosch presented encouraging survival data on 51 patients suffering with Glioblastoma multiforme ... Read more

March 30, 2015March 30, 2015

Immunotherapy Delays Recurrence Of Both Stage III And IV Ovarian Cancers

News

A recent study whose results were presented during the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Chicago found that personalized medicine is getting closer to reality for ... Read more

February 26, 2015February 26, 2015

Immune Checkpoint Protein Blockade And Low Dose Entire Body Irradiation Identified As Myeloma Immunotherapy

News

According to a recent study published in the Journal for Immunotherapy of Cancer and titled “Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma,“ blocking a combination of ... Read more

February 19, 2015February 19, 2015

Lycera Announces Research On Anti-Cancer Activity Of Oral Immunotherapy Candidates

News

Lycera Corp. is a biopharmaceutical company focused on the development of breakthrough drugs to address cancer and autoimmune diseases. The firm recently announced that very promising data related to the activity of an anti-tumoral RORgamma agonist ... Read more

February 12, 2015February 12, 2015

TLR9: A New Immunotherapeutic Approach Against Cancer

News

Researchers from the University of Tokyo have shed light on how Toll-like receptor 9 (TLR9) can bind itself to pathogen DNA and, consequently, activate the innate immune system. This finding is crucial for the creation ... Read more

January 23, 2015January 23, 2015

The Immune System Has Crucial Role In Viral Therapy’s Effectiveness Against Tumors

News

According to a recent study, published in the Molecular Therapy–Oncolytics journal, viral therapy for childhood cancer could improve if chemotherapy and other treatments did not suppress the immune system. The research team, led by Timothy ... Read more

December 1, 2014December 1, 2014

STING Pathway Is The Key to Tumor Immunity

News

According to two different studies published in the November issue of the journal Immunity, it was recently found that a protein complex known as STING (STimulator of INterferon Genes) can detect the presence of ... Read more

November 24, 2014November 24, 2014

3SBio And PharmAbcine Sign Agreement For Tanibirumab

News

3SBio Inc. has announced the establishment of an exclusive license agreement with PharmAbcine Inc. for the development, marketing and manufacturing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer treatment, to be marketed in the Asiatic ... Read more

November 19, 2014November 19, 2014

Chemo Might Be Replaced With Immuno-Oncology Drug To Treat Melanoma

News

Bristol-Myers Squibb Co. revealed results of a study suggesting that treating patients suffering with advanced melanoma, the most deadliest form of skin cancer, through chemotherapy may become obsolete. The study, presented at the Melanoma Research ... Read more

November 14, 2014November 18, 2014

PD-1 And PD-L1 Inhibitors Can Be Expanded To Wide Variety Of Cancers

News

Caris Life Sciences announced a publication in which the company’s Caris Molecular Intelligence™ system showed the potential of investigating the expression of two immune checkpoint proteins, the programmed cell death protein 1 (PD-1) and the programmed cell ... Read more